慢性创伤护理市场－2026-2031年预测

预计慢性创伤护理市场将从 2025 年的 131.62 亿美元成长到 2031 年的 168.94 亿美元，复合年增长率为 4.25%。

慢性创伤护理市场是全球医疗设备和先进疗法领域中一个重要且不断增长的细分市场，专注于治疗无法经历正常癒合过程的伤口。这些伤口包括糖尿病足溃疡、静脉性腿部溃疡、压疮和动脉溃疡，由于其复杂的病理生理机制、高復发率以及与潜在疾病的关联，造成了巨大的临床和经济负担。该市场涵盖了广泛的产品和治疗方法，从先进的伤口敷料和生物活性剂到负压伤口治疗（NPWT）设备以及新兴的再生医学解决方案。强劲的非週期性人口和流行病学趋势是推动市场成长的根本动力。

主要市场成长要素

市场扩张受多种相互关联的人口和疾病因素所驱动。其中一个关键驱动因素是全球糖尿病盛行率的不断上升。糖尿病足溃疡（DFU）是严重的併发症，治疗费用高昂，对患者造成很高的终生风险。神经病变、缺血和易感染病理学特征构成了一个极具挑战性的癒合环境，从而持续推动对专用负重装置、抗菌敷料、生长因子和其他先进干预措施的需求，以防止病情发展至截肢。

此外，世界人口老化也进一步加剧了这个问题。老年人因活动能力下降（导致压疮）、组织灌注减少、静脉功能不全等合併症发生率较高等因素，罹患慢性伤口的风险呈指数级增长。这种人口结构变化，即人口老化，与静脉性腿部溃疡和压疮的发生率直接相关，不可避免地导致需要长期、往往复杂的伤口管理的患者群体不断扩大。

此外，多种基础疾病的存在会显着加重患者的负担。慢性伤口常作为继发性併发症出现于免疫功能、循环功能或组织完整性受损的疾病患者中，例如心血管疾病、癌症（及其治疗）、自体免疫疾病和肾衰竭患者。对于患有复杂多系统疾病的患者而言，伤口管理至关重要，因此创伤护理是一项多学科协作的临床挑战。

主要市场限制因素

先进创伤护理产品和治疗方法的高昂成本是限制市场成长和患者取得这些产品的主要因素。先进的敷料、负压伤口治疗系统、皮肤替代物和细胞疗法都涉及大量的材料和技术成本。这种经济负担可能会限制注重成本的医疗系统采用这些产品，造成医疗服务取得的差距，并导致报销方面的难题。为了应对这些经济压力，需要强有力的临床证据来证明这些先进干预措施的合理性，并展现出更优的疗效，例如更快的癒合速度、更低的感染率以及因避免住院和手术而降低的长期成本。

区域展望：北美市场表现强劲

预计北美将在全球慢性创伤护理市场占据重要份额。这一地位得益于多种因素的共同作用，包括完善的医疗保健基础设施和先进医疗技术的高度普及、庞大的老龄人口和日益增长的糖尿病患病率，以及与其他许多地区相比相对有利的创新创伤护理产品报销环境。此外，该地区还聚集了众多领先的医疗设备和生技公司，这些公司不断推动新解决方案的研发和商业化，进一步巩固了主导地位。

竞争格局及创新重点

该市场构成多元化，参与者包括大规模跨国医疗设备公司、专业创伤护理公司和生物技术公司。竞争主要体现在产品有效性、临床证据、医护人员和患者的易用性以及强大的分销网络等方面。策略创新主要集中在以下几个关键领域：

• 先进的生物活性敷料：开发下一代敷料，透过持续的抗菌活性、蛋白酶调节和生长因子传递来主动调节伤口微环境。
• 再生医学：细胞和组织产品（CTP）的进展，包括同种异体和自体皮肤替代物、干细胞疗法和胎盘组织基质，旨在直接促进停滞伤口的癒合。
• 数位健康整合：将连网感测器整合到敷料和负压伤口治疗 (NPWT) 设备中，可远端监测伤口状况、温度和渗出液水平，从而支援早期疗育和个人化护理计划。
• 照护现场诊断：开发快速床边评估伤口生物标记、细菌负荷和血流的方法，以指导有针对性的实证治疗选择。

未来展望与战略考量

慢性创伤护理市场预计将持续成长，这主要受人口老化这一不可逆转的趋势以及全球糖尿病负担日益加重的推动。未来，该市场的发展趋势将从通用通讯协定转向个人化伤口管理，利用诊断工具，根据患者特定的伤口病因和生物标记特征，选择最合适的先进治疗方案。

对于行业相关人员，策略成功取决于能否产生高品质的真实世界证据，以支持基于价值的定价策略并获得有利的报销。为新兴市场开发具有成本效益的解决方案、与综合医疗网络和居家医疗机构建立合作关係，以及创建包含患者教育和依从性在内的综合支持项目，将变得日益重要。随着对基于价值的医疗保健的日益重视，能否证明产品不仅具有疗效，还能改善患者的生活品质并降低整体医疗成本，将决定企业在这个重要且快速增长的治疗领域中的市场领导地位。

本报告的主要优势：

• 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用洞察力，做出策略决策，在动态环境中发展新的业务流和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2021年至2025年的实际数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区分類的收入和预测评估，包括国家/地区
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

5. 慢性创伤护理市场（按类型划分）

• 介绍
• 糖尿病溃疡
• 压疮
• 静脉溃疡
• 其他的

6. 慢性创伤护理产品市场

• 介绍
• 进阶伤口敷料
• 伤口护理
• 积极治疗
• 其他的

7. 按最终使用者分類的慢性创伤护理市场

• 介绍
• 医院及创伤护理中心
• 居家医疗环境
• 其他的

8. 各地区慢性创伤护理市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Smith and Nephew
• Cardinal Health
• Coloplast
• 3M
• Tissue Regenix
• Integra Lifesciences
• ConvaTec Inc.
• Molnlycke Health Care AB
• B Braun Melsungen AG.

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

The chronic wound care market is projected to expand at a 4.25% CAGR, attaining USD 16.894 billion in 2031 from USD 13.162 billion in 2025.

The chronic wound care market represents a critical and expanding segment within the global medical device and advanced therapy sector, focused on the management of wounds that fail to progress through the normal stages of healing. These wounds, which include diabetic foot ulcers, venous leg ulcers, pressure ulcers, and arterial ulcers, present a significant clinical and economic burden due to their complex pathophysiology, high recurrence rates, and association with underlying comorbidities. The market encompasses a wide range of products and therapies, from advanced wound dressings and bioactive agents to negative pressure wound therapy (NPWT) devices and emerging regenerative medicine solutions. Growth is fundamentally driven by powerful, non-cyclical demographic and epidemiological trends.

Primary Market Growth Drivers

The expansion of the market is underpinned by several powerful and interrelated demographic and disease factors. A primary driver is the global rise in the prevalence of diabetes mellitus. Diabetic foot ulcers (DFUs) are a severe and costly complication, with a high lifetime risk for patients. The pathophysiological triad of neuropathy, ischemia, and susceptibility to infection creates a challenging healing environment, driving sustained demand for specialized offloading devices, antimicrobial dressings, growth factors, and other advanced interventions aimed at preventing progression to amputation.

This is compounded by the worldwide aging of the population. Older adults are at exponentially higher risk for developing chronic wounds due to factors such as reduced mobility (leading to pressure injuries), decreased tissue perfusion, and higher rates of comorbid conditions like venous insufficiency. The demographic shift towards larger elderly populations directly correlates with increased incidence of venous leg ulcers and pressure injuries, ensuring a growing patient pool requiring long-term, often multi-modal, wound management.

Furthermore, the presence of multiple underlying systemic conditions contributes significantly to the patient burden. Chronic wounds frequently arise as secondary complications in individuals with conditions that impair immune function, circulation, or tissue integrity. This includes patients with cardiovascular diseases, cancer (and its treatments), autoimmune disorders, and renal failure. The management of these wounds is integral to the overall care of patients with complex, multi-system diseases, making wound care a cross-disciplinary clinical challenge.

Key Market Restraint

A significant constraint on market growth and patient access is the high cost associated with advanced wound care products and therapies. Advanced dressings, NPWT systems, skin substitutes, and cellular therapies involve substantial material and technology costs. This financial burden can limit adoption in cost-sensitive healthcare systems, create access disparities, and pose challenges for reimbursement. The economic pressure necessitates robust clinical evidence demonstrating that these advanced interventions lead to superior outcomes, such as faster healing times, reduced infection rates, and lower long-term costs through avoided hospitalizations and surgeries, to justify their expenditure.

Geographical Outlook: North American Market Strength

North America is expected to hold a significant share of the global chronic wound care market. This position is supported by a confluence of factors: a well-established healthcare infrastructure with high adoption rates of advanced medical technologies, a large and growing population of aging adults and individuals with diabetes, and a relatively favorable reimbursement environment for innovative wound care products compared to many other regions. Additionally, the presence of many leading medical device and biotechnology companies within the region drives continuous research, development, and commercialization of new solutions, further consolidating its market leadership.

Competitive Landscape and Innovation Focus

The market is served by a diverse group of players, including large multinational medical device corporations, specialized wound care companies, and biotechnology firms. Competition is based on product efficacy, clinical evidence, ease of use for clinicians and patients, and the strength of distributor networks. Strategic innovation is directed toward several key areas:

• Advanced Bioactive Dressings: Development of next-generation dressings that actively modulate the wound microenvironment with sustained antimicrobial activity, protease modulation, and growth factor delivery.
• Regenerative Medicine: Advancement of cellular and tissue-based products (CTPs), including allogeneic and autologous skin substitutes, stem cell therapies, and placental tissue matrices designed to directly stimulate healing in stalled wounds.
• Digital Health Integration: Incorporation of connected sensors into dressings and NPWT devices to enable remote monitoring of wound status, temperature, and exudate levels, facilitating early intervention and personalized care plans.
• Point-of-Care Diagnostics: Development of tools for rapid, bedside assessment of wound biomarkers, bacterial load, and perfusion to guide targeted, evidence-based treatment selection.

Future Trajectory and Strategic Considerations

The chronic wound care market is poised for sustained growth, driven by the irreversible demographic trends of population aging and the rising global burden of diabetes. Future evolution will be characterized by a shift from generalized protocols toward personalized wound management, leveraging diagnostic tools to select the most appropriate advanced therapy for a patient's specific wound etiology and biomarker profile.

For industry participants, strategic success will hinge on generating high-quality real-world evidence to support value-based pricing and secure favorable reimbursement. Developing cost-effective solutions for emerging markets, forging partnerships with integrated delivery networks and home health agencies, and creating comprehensive support programs that encompass patient education and adherence will be increasingly important. As the focus on value-based care intensifies, the ability to demonstrate not just product performance but also improvements in patient quality of life and reductions in total cost of care will define market leadership in this essential and growing therapeutic area.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Chronic Wound Care Market Segmentation

• By Type
• Diabetic Ulcers
• Pressure Ulcers
• Venous Ulcers
• Others
• By Product
• Advanced Wound Dressings
• Wound Care Therapy
• Active Therapy
• Others
• By End-User
• Hospitals and Wound Care Centers
• Homecare Settings
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CHRONIC WOUND CARE MARKET BY TYPE

• 5.1. Introduction
• 5.2. Diabetic Ulcers
• 5.3. Pressure Ulcers
• 5.4. Venous Ulcers
• 5.5. Others

6. CHRONIC WOUND CARE MARKET BY PRODUCT

• 6.1. Introduction
• 6.2. Advanced wound dressings
• 6.3. Wound care therapy
• 6.4. Active therapy
• 6.5. Others

7. CHRONIC WOUND CARE MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals and wound care centers
• 7.3. Homecare settings
• 7.4. Others

8. CHRONIC WOUND CARE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Smith and Nephew
• 10.2. Cardinal Health
• 10.3. Coloplast
• 10.4. 3M
• 10.5. Tissue Regenix
• 10.6. Integra Lifesciences
• 10.7. ConvaTec Inc.
• 10.8. Molnlycke Health Care AB
• 10.9. B Braun Melsungen AG.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations